Lineage Cell Therapeutics

LCTXNYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$241.957 M

$0.96 -8.01%

Close of 23 Sept 2026

Revenue

$14.6M

#3079 by revenue

Earnings

-$63.5M

Loss-making

Shares outstanding

252,907,464

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#87InvivydIVVD$272.1M
#88Sutro BiopharmaSTRO$260.8M
#89Lineage Cell TherapeuticsLCTX$242.0M
#90Protalix BioTherapeuticsPLX$225.6M
#91AlectorALEC$225.5M

What if Lineage Cell Therapeutics were worth as much as…

Open the what-if tool →

Gold $29.8T

$118,015.21

Per share 123,357× higher

Bitcoin $1.69T

$6,698.58

Per share 7,002× higher

Nvidia $5.43T

$21,489.25

Per share 22,462× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Lineage Cell Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.